The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00103597




Registration number
NCT00103597
Ethics application status
Date submitted
11/02/2005
Date registered
14/02/2005
Date last updated
20/10/2005

Titles & IDs
Public title
Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
Scientific title
Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
Secondary ID [1] 0 0
2004/135
Secondary ID [2] 0 0
2004/135
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Parkinson's Disease 0 0
Multiple System Atrophy 0 0
Orthostatic Hypotension 0 0
Condition category
Condition code
Neurological 0 0 0 0
Parkinson's disease
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Neurological 0 0 0 0
Other neurological disorders
Neurological 0 0 0 0
Neurodegenerative diseases
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fludrocortisone
Treatment: Drugs - Domperidone
Behaviour - Conservative Measures for Orthostatic Hypotension

Treatment: Drugs: Fludrocortisone


Treatment: Drugs: Domperidone


Behaviour: Conservative Measures for Orthostatic Hypotension


Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Behaviour
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Efficacy of conservative treatment, domperidone, and fludrocortisone for patient's subjective symptoms of orthostatic hypotension, and on objective autonomic testing
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
- Patients residing in Queensland Australia

- Age 40-95

- Parkinson's Disease or MSA diagnosed by a neurologist

- Symptoms of orthostatic hypotension, as defined by 2 validated questionnaires
Minimum age
40 Years
Maximum age
95 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with acute cardiomyopathy or cardiac condition

- Patients unable to give consent

- Patients not stable on their Parkinsonian medications

- Patients with another cause for autonomic neuropathy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
Royal Brisbane and Women's Hospital - Brisbane
Recruitment postcode(s) [1] 0 0
4029 - Brisbane

Funding & Sponsors
Primary sponsor type
Other
Name
Royal Brisbane and Women's Hospital
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Patients with Parkinson's Disease or Multiple System Atrophy (MSA), and symptoms of
orthostatic hypotension, are eligible for the study. Each patient will have three weeks of
conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy
with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing,
and Unified Parkinson Disease Rating Scale (UPDRS) will be performed after each intervention.
Trial website
https://clinicaltrials.gov/show/NCT00103597
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Kerrie Schoffer, MBBS
Address 0 0
Movement Disorders Fellow
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications